About Revance

Nestled in California’s legendary Silicon Valley, the epicenter of life-changing technology and healthcare innovation, Revance stands poised to enter, if not redefine, the neurotoxin aesthetic and therapeutic product categories.

Our Trajectory to Commercial Success

Revance is more than a biotechnology company taking an innovative approach to neurotoxin delivery. We are the integrated sum of our many strengths.

Deep knowledge of drug development, scientific acumen, and prior commercialization experience will enable our team of experts to bring to market a focused portfolio of product candidates that achieve multiple strategic objectives.

Our trajectory to commercial success begins with the development and delivery of our next-generation neurotoxin, daxibotulinumtoxinA, Revance’s highly purified botulinum toxin type A.

Proof of Concept

We like to dream and think big. Our organization owns aspirations of becoming a global leader in both aesthetic medicine and underserved therapeutic specialties such as dermatology, neurology, musculoskeletal disorders, urology and ophthalmology.

Currently, Revance is advancing investigational product candidate RT002.

Currently, Revance is advancing investigational product candidate RT002 injectable. RT002 has the potential to expand practitioner and patient utilization, with the opportunity to capture, retain and grow significant market share. In anticipation of entering the $3.4 billion neurotoxin market, Revance’s potential long-acting injectable neurotoxin is being lauded as a possible game-changer by industry insiders.

While our first indication will likely be in aesthetic medicine to treat glabellar (frown) lines, we plan to follow with therapeutic options that deliver lasting results, irrespective of use area. Our ultimate mission is to improve the current state of patient care and enhance the overall patient experience. We know it can be done and we intend to prove it.

Read More >>

Focused Clinical Program

In clinical trials with investigational product candidate (RT002), daxibotulinumtoxinA has shown potential of becoming the first long-lasting injectable formulation of botulinum toxin type A. The anticipated approval of RT002 injectable would represent the first major innovation to hit the neurotoxin market in 30 years.

A well-defined regulatory path to approval puts Revance on track...

A well-defined regulatory path to approval puts Revance on track to pursue multiple indications and conceivably transform both the anti-aging market and neurotoxin treatment categories. The company’s initial aesthetic and therapeutic product portfolio should prove attractive to a diverse group of medical specialists and patients in need.

Read More >>

Remarkable Science Changes Everything

Combining TransMTS peptide companion technology with active drug macromolecules such as daxibotulinumtoxinA may help address currently unfulfilled needs in aesthetic medicine and various therapeutic categories. Employing TransMTS may ensure overall formulation performance of the RT002 injectable where the focus is on delivering the first potentially long-acting neurotoxin. With novel as well as multiple indication areas in clinical development, the company’s DaxibotulinumtoxinA compound is often referred to as “A pipeline within a product.”

Revance’s peptide companion technology, TransMTS®, is a proprietary excipient that can be formulated with various macromolecules such as daxibotulinumtoxinA.

Envisioning Future Opportunities

Revance is intensely focused on the advancement of remarkable science that can improve the way drugs perform today and in the future.

It’s no secret that Revance maintains grand ambitions of developing and commercializing the RT001 topical daxibotulinumtoxinA product candidate in hope of becoming the first-ever, needle-free topical botulinum toxin product. As we re-enter preclinical development, our initial plan is to further characterize RT001. In time, we will investigate the potential for topical application across areas of greatest need, and where an innovation of this magnitude would provide meaningful advantages over injectable administration.

Beyond daxibotulinumtoxinA, Revance believes a variety of active compounds and other macromolecules are potentially suitable for use with the company’s patented TransMTS peptide companion technology. Additional applications for TransMTS potentially range from over-the-counter beauty products to prescription drugs used daily to treat chronic diseases.

Fueled by innovation and entrepreneurial spirit, our vision is to enhance the standard of care for patients around the world. By continuously pursuing product improvements and delivering next-generation therapies, we believe we can transcend today’s possibilities.

Read More >>

C-Suite Perspective

Abhay Joshi, Ph.D.
Abhay Joshi, Ph.D.
Chief Operating Officer

Shattering Age-Old Barriers

I joined Revance with one goal in mind — to deliver on the tremendous promise held by TransMTS®, our proprietary peptide companion technology. Yet, for me, it is never just about science alone. Rather, it is about translating science and technology into remarkable benefits appreciated by patients and physicians around the globe, and it is about product differentiation in the market place. It’s about elevating the state of patient care. These are no small feats, yet I believe these to be achievable improvements worthy of our team’s collective ambition and unwavering commitment.

Today at Revance, our team is poised on the threshold of achieving a corporate vision that began over a decade ago. That vision is to deliver a revolutionary breakthrough in the field of neuromodulator therapy. By formulating the company’s highly purified botulinum toxin with TransMTS® peptide technology, we advance ever closer to realizing the previously unthinkable — the first long-lasting neurotoxin treatment, DaxibotulinumtoxinA for Injection (RT002). Far more than an incremental innovation, this unique combination of toxin and TransMTS® creates newfound value in both aesthetic medicine and therapeutic specialties.

In clinical science, as only the experienced know, plans are laid for success while anticipating and preparing for challenges. Revance’s daxibotulinumtoxinA compound and robust clinical program have captured the attention of interested investors and physicians, established competitors notwithstanding. It is with complete confidence that I report to you that our therapeutic and aesthetic clinical programs are proceeding as planned. Furthermore, I am delighted to announce the addition of Revance’s newest Phase 2 clinical trial in plantar fasciitis. Plantar fasciitis is an extremely painful and debilitating musculoskeletal condition estimated to effect nearly 10% of people at some point during their life. With RT002 injectable, Revance plans to pursue this highly novel therapeutic indication — an important first in the category.

As COO, my passion and my focus revolve around leading team operations, cultivating our expert talent, and assuring executional excellence every step of the way. Whether sourcing the purest ingredients needed to manufacture our next-generation neurotoxin, ensuring our clinical trials are delivered on schedule, or scaling our organization for product commercialization, our team is ready for the next steps on the daxibotulinumtoxinA development trajectory. As a team, we will see it through.

It is a truly exciting time in the history of this organization, and there is virtually nothing to hold us back from realizing product enhancements eagerly awaited by patients and physicians. Innovation in our lab will only be surpassed by a true breakthrough in the clinic. Here at Revance, consistent performance and sound execution are the means to a remarkable end result. For us, shattering age-old barriers is the new reality.

Management Team

Dan Browne, President & Chief Executive Officer
Dan Browne
Co-Founder, President & Chief Executive Officer

Daniel Browne is a co-founder of the company and has served as our President, Chief Executive Officer and a member of the board of directors since operations commenced in 2002... LEARN MORE >>. Prior to joining Revance, Mr. Browne served as President and Chief Executive Officer of Neomend, Inc., a medical technology and biomaterials company; from 2001 to 2003 and from 1997 to 2000 he served as President of Prograft Medical Inc., both companies in the medical technology industry. Previously, Mr. Browne spent more than 16 years in various leadership positions in product development, sales and marketing and business development in the Gore Medical Products Division of W.L. Gore & Associates, Inc., a global technology company, serving as Business Leader in the Medical Products Division as his final role at the company. Mr. Browne holds a B.S. from the University of Hawaii in Cell and Molecular Biology and an M.B.A. from Pepperdine University. << CLOSE

Abhay Joshi, Ph.D., M.B.A.
Abhay Joshi, Ph.D., M.B.A.
Chief Operating Officer

Dr. Abhay Joshi joined Revance as our Chief Operating Officer in December 2015. From 2007 to 2015, he was the President and Chief Executive Officer of Alvine Pharmaceuticals... LEARN MORE >>, a privately held clinical stage company focused on the development of biologics targeting autoimmune and inflammatory diseases. He also served as an Executive Vice President and Chief Technical Officer at CoTherix, Inc., which was acquired by Actelion Ltd in 2007. Prior to CoTherix, Dr. Joshi was the Vice President of Global Technical Operations, Specialty Pharmaceuticals at Allergan, Inc. where he was responsible for the company’s global biologics manufacturing operations for BOTOX® and its Latin America and Asia Pacific pharmaceutical operations, and held a series of senior management positions. He serves on the Boards of Alvine Pharmaceuticals and Genyous Biomed International. Dr. Joshi received his B.Tech in Chemical Engineering from the Indian Institute of Technology (IIT), New Delhi, an M.S.E. and a Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, and an M.B.A. from the University of California, Irvine. << CLOSE

Lauren Silvernail
Lauren Silvernail
Chief Financial Officer and Chief Business Officer

Lauren Silvernail has served as our Chief Financial Officer since March 2013 and as Chief Business Officer since December 2015. From 2003 to 2012, Ms. Silvernail was Chief Financial Officer and Vice President of Corporate Development... LEARN MORE >> at ISTA Pharmaceuticals, Inc., where she was integral to growing revenues to more than $160 million and headcount to more than 340 employees before the company was purchased by Bausch + Lomb in June 2012. From 1995 to 2003, she served in various operating and corporate development positions with Allergan, Inc., a multi-specialty healthcare company, including her final role at the company, Vice President, Business Development. Prior to joining Allergan, Inc., Ms. Silvernail worked at Glenwood Ventures, an investment firm, as a General Partner. She currently serves on the Board of Directors of Nicox S.A. Ms. Silvernail holds a B.A. in Biophysics from the University of California, Berkeley and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles. Ms. Silvernail is a member of the Licensing Executives Society (LES). << CLOSE

Todd Zavodnick
Todd Zavodnick
Chief Commercial Officer and President, Aesthetics & Therapeutics

Todd Zavodnick has served as our Chief Commercial Officer and President, Aesthetics & Therapeutics since September 2017. Mr. Zavodnick joined Revance from ZELTIQ Aesthetics, Inc., developer and marketer of the #1... LEARN MORE >> non-invasive fat-reduction procedure known as CoolSculpting, where he was President of International prior to the company’s acquisition by Allergan plc on April 28, 2017. Previously, he served in leadership roles at Galderma Laboratories, most recently as President and General Manager, North America. Prior to this, Mr. Zavodnick managed a successful 14-year career at Alcon Laboratories in a series of ascending sales and marketing positions both domestically and internationally, ultimately serving as President of Alcon China and Mongolia. He serves on the Board of Directors for NovaBay Pharmaceuticals (NYSE: NBY), Inc., Allurion Technologies, and the Children’s Skin Disease Foundation. Mr. Zavodnick holds a M.B.A. from The University of Texas at Dallas and a B.S. in Pharmacy from Rutgers University. << CLOSE

Roman G. Rubio, M.D.
Roman G. Rubio, M.D.
Senior Vice President, Clinical Development

Dr. Roman Rubio joined Revance as our Senior Vice President of Clinical Development in March of 2016. Dr. Rubio came to Revance from Avalanche Biotechnologies, Inc., where... LEARN MORE >> he was Senior Vice President of Translational Medicine. Prior to Avalanche, Dr. Rubio served more than 11 years at Genentech, Inc., ascending through a number of clinical and development management roles to Global Head of Ophthalmology. There he played key leadership roles in the successful development and approval of several ophthalmic indications for Genentech’s Lucentis® (ranibizumab injection). Dr. Rubio has an MBA in Health Care Management and Finance from The Wharton School, University of Pennsylvania, and received his Doctor of Medicine from University of California, San Francisco He currently serves on the Board of Trustees for the American Foundation for the Blind. << CLOSE

Mukul Agarwal
Mukul Agarwal
Vice President, Business Development

Mukul Agarwal joined Revance as our Vice President, Business Development in November 2016 with responsibility for corporate development, partnering & licensing, and alliance management. LEARN MORE >>He has over 15 years of experience in drug development & commercialization and has led and supported multiple successful M&A, licensing, and JV transactions (both buy and sell side). Prior to Revance, Mr. Agarwal held the role of Senior Director of Corporate Development and Strategy at Anacor (acquired by Pfizer). He has had roles in BD&L, Global Commercial/Marketing, Finance, and Strategy functions at Forest Pharma (now Allergan), MedImmune (acquired by AZ), GSK and Genentech. Earlier in his career, Mr. Agarwal was a management consultant with PRTM (now PriceWaterhouse Coopers) with a focus on corporate strategy and functional operational excellence for Biotech/Pharma clients. He started as a bench scientist at a start-up. Mr. Agarwal received his M.B.A. from Carnegie Mellon University, M.S. from Ohio State University, and B.S. from Indian Institute of Technology, Delhi.  << CLOSE

Justin Ford
Justin Ford
Vice President, Human Resources and Head of People

Justin Ford joined Revance in June of 2017. He has more than 30 years of experience building, developing and aligning organizational and cultural capabilities to impact... LEARN MORE >> profitability, growth, business priorities and employee engagement. Justin came to Revance from Raptor Pharmaceuticals, a rare disease biopharmaceutical company (acquired by Horizon Pharma), where he was Senior Vice President of Human Resources. Prior to Raptor, he served as Global VP of HR and Administration at Micromet, Inc. and as Global VP, HR with Bayer Pharmaceuticals. Justin also held other Human Resources leadership positions at Monsanto, Givaudan, Washington University in St. Louis, Engelhard (BASF), and Newport News Shipbuilding. Justin has a B.A. in Human Resources from The University of Kansas. He is a Certified Compensation Professional and has completed the curriculum and taught at the Advanced Program in Human Resource Management at The John Anderson Graduate School of Management at UCLA. << CLOSE

Azita Nejad
Azita Nejad
Vice President, Quality and Validations

Azita Nejad joined Revance in September of 2014 as Vice President, Quality. She has more than 25 years of experience in all aspects of quality and compliance. From 2007 to 2013, Ms. Nejad held... LEARN MORE >> the positions of Director/Senior Director, Quality at Gilead Sciences, Inc. responsible for quality and compliance of product development, regulatory submissions and/or PAI management for products such as Complera®, Stribild®, and Sovaldi®. Previous to Gilead, Ms. Nejad was at CV Therapeutics as Director, Quality responsible for all aspects of quality for clinical and commercial products. Ms. Nejad has a B.S. in Chemistry from the University of Colorado. << CLOSE

Erica Bazerkanian
Erica Bazerkanian
Head, Strategic Marketing

Erica Bazerkanian joined Revance as senior director, strategic marketing in September of 2015. She has more than 20 years of experience in healthcare marketing, including new product development, strategic... LEARN MORE >> market planning, and product launch. Prior to her full-time position at Revance, Ms. Bazerkanian was a retained consultant in its marketing group. From 2006-2013, Ms. Bazerkanian was senior director, marketing at Kythera Biopharmaceuticals, where she led the market and brand development efforts for Kybella, the company’s lead product. Prior to joining Kythera, Ms. Bazerkanian spent five years at Amgen with roles of increasing responsibility in the launches of ARANESP®, NEULASTA® and VECTIBIX®. Ms. Bazerkanian received a B.A. with honors in Communications and Political Science from University of Washington and an M.B.A. in Healthcare Management from The Wharton School, University of Pennsylvania. << CLOSE

Jeanie D. Herbert
Jeanie D. Herbert
Senior Director, Investor Relations and Corporate Communications

Jeanie Herbert joined Revance as Senior Director of Investor Relations in January 2015 after serving as the company’s investor relations consultant since its IPO. LEARN MORE >>With more than 30 years of experience in corporate communications and investor relations, Ms. Herbert has driven shareholder value at companies in the biotechnology, medical device, specialty pharmaceutical and technology fields. Prior to Revance, Ms. Herbert was Director of Surgical Communications for Bausch + Lomb (acquired by Valeant). In prior roles, Ms. Herbert served as the Director of Investor Relations for ISTA Pharmaceuticals, QLogic Corporation, Leap Wireless International (known for its Cricket wireless brand) and Beckman Coulter. Ms. Herbert as an M.A. in Management from The Peter Drucker Executive Management Program at the Claremont Graduate School and a B.A. from California State University, Fullerton. << CLOSE

Board of Directors

Angus Russell
Angus C. Russell
Chairman of the Board

Angus Russell has served as Chairman of the Board since March 2014. Mr. Russell is a veteran in the global biopharmaceutical industry with over 30 years of experience in commercial execution, operations, and strategic acquisitions. He has served on the Board of Directors at Mallinckrodt, since August 2014, BioTime, Inc. since December 2014, and TherapeuticsMD, Inc. since March 2015. Mr. Russell also served as a Director at Shire Plc from 1999 to 2013. During his tenure at Shire Plc, Mr. Russell served as CEO from 2008 to 2013 and CFO from 1999 to 2008. While CEO at Shire, Mr. Russell was also the Chair of Shire’s Leadership Team and a lead member of the Shire Management Committee, which designed and implemented Shire’s immensely successful long-term business strategy. Prior to joining Shire, Mr. Russell served at ICI, Zeneca, and AstraZeneca in various senior positions including VP of Corporate Finance at AstraZeneca. << CLOSE

Dan Browne
Dan Browne
Co-Founder, President & CEO of Revance Therapeutics, Inc.

Daniel Browne is a co-founder of the company and has served as our President, Chief Executive Officer and a member of the board of directors since operations commenced in 2002. Prior to joining Revance, Mr. Browne served as President and Chief Executive Officer of Neomend, Inc., a medical technology and biomaterials company; from 2001 to 2003 and from 1997 to 2000 he served as President of Prograft Medical Inc., both companies in the medical technology industry. Previously, Mr. Browne spent more than 16 years in various leadership positions in product development, sales and marketing and business development in the Gore Medical Products Division of W.L. Gore & Associates, Inc., a global technology company, serving as Business Leader in the Medical Products Division as his final role at the company. Mr. Browne holds a B.S. from the University of Hawaii in Cell and Molecular Biology and an M.B.A. from Pepperdine University. << CLOSE

Robert Byrnes
Robert Byrnes
Chair – Compensation Committee

Robert Byrnes has served as a director of our company since August 2004. Mr. Byrnes has spent over 40 years in the medical device and biotechnology industries. From October 1997 until October 2002, and again from January 2005 to the present, he has served as the President and Chief Executive Officer of Roan, Inc., an advisory service for healthcare organizations. From November 2002 to January 2005, Mr. Byrnes served as the President and Chief Executive Officer of Thermage, Inc., a medical device company focused on the non-invasive treatment of wrinkles. He has also served as Chairman and Chief Executive Officer of Tokos Medical Corporation, a health care services company, President of Caremark RX, Inc., a retail pharmacy and healthcare company, and Vice President of Marketing and Business Development for Genentech, Inc., a biotechnology company. Mr. Byrnes holds a B.S. in Pharmacy from Ferris State University and an M.B.A in Marketing and Finance from Loyola University, Chicago. << CLOSE

Mark Foley
Mark Foley
Chair – Audit Committee

Mark Foley has served as a Board member of our company since September 2017. Mr. Foley has more than 25 years of operational and investment experience in the healthcare arena. He is currently Managing Director of RWI Ventures, a venture capital firm focused on life sciences, networking, semiconductor and software investments. Previously, Mr. Foley was Chairman, President and CEO of ZELTIQ Aesthetics (ZLTQ), serving from 2012 through the company’s acquisition in 2017 by Allergan (AGN) for $2.5 billion. During his tenure, he led ZELTIQ’s growth from $68 million in annual revenue in 2012 to over $350 million in 2016. Prior to ZELTIQ, Mr. Foley held a variety of senior operating roles in large public companies and venture-backed startups, including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic) where he was the founder and CEO. He is a board member at Glaukos (GKOS) and also serves as Chairman of ULab and HintMD. Mr. Foley received a Bachelor of Arts degree from the University of Notre Dame. << CLOSE

Phyllis Gardner
Phyllis Gardner, M.D.

Phyllis Gardner, M.D. has served as a director since December 2006. Dr. Gardner has spent over 35 years in academia, medicine and industry. She served as an adjunct Partner at Essex Woodlands, a growth equity firm that focuses on the healthcare industry, where she worked from June 1999 to 2014. Dr. Gardner has served on the board of directors of several public and private companies. She began her academic medical career at Stanford University, where she has held several positions, including Senior Associate Dean for Education and Student Affairs and she remains today as Professor of Medicine. From 1994 to 1996, she took a leave of absence from Stanford University to serve as Principal Scientist, Vice President of Research and Head of ALZA Technology Institute, a major drug delivery company. Dr. Gardner holds a B.S. from the University of Illinois and an M.D. from Harvard University. << CLOSE

Julian S. Gangolli
Julian S. Gangolli

Julian S. Gangolli has served as a director since July 2016. He is President, North America of GW Pharmaceuticals Inc., spearheading the buildout of the company’s U.S. commercial infrastructure in advance of the potential launch of its lead therapeutic candidate, Epidiolex® (cannabidiol or CBD), which is in late-stage development for a number of child-onset epilepsy syndromes. Mr. Gangolli is also a director of GW Pharmaceuticals PLC. Prior to joining GW Pharma, Mr. Gangolli served as President of the North American Pharmaceutical division of Allergan Inc. for 11 years, where he was responsible for a 1,400 person integrated commercial operation with sales exceeding $3.8 billion in 2014. Previously, he served as Senior Vice President, U.S. Eye Care at Allergan, during which time this division launched eight new products, helping to propel growth at more than 20% a year over a 5-year period. Prior to Allergan, Mr. Gangolli served in increasingly senior sales and marketing positions at VIVUS, Inc., Syntex Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd in the UK. Mr. Gangolli received a BSc (Honors) degree in Applied Chemistry and Business Studies from Kingston University in England. << CLOSE

Philip Vickers
Philip J. Vickers
Chair – Science & Technology

Philip J. Vickers, Ph.D. has served as a director at Revance since February 2015. Dr. Vickers has spent over 25 years in the pharmaceutical industry. From 2011 to 2017 he served as Global Head of Research and Development at Shire where he was responsible for overseeing preclinical research, clinical development, regulatory affairs, and medical affairs. Dr. Vickers was also a member of Shire’s Executive Committee and chaired the companies Pipeline Committee. Prior to Shire, he was Chief Scientific Officer and President at Resolvyx Pharmaceuticals, a biopharmaceutical company, from 2009 to 2011, where he was a member of the board of directors. Prior to Resolvyx, he served in various capacities with international biopharmaceutical companies including Boehringer-Ingelheim, Pfizer and Merck. Dr. Vickers was a Visiting Fellow at the National Cancer Institute in Bethesda, Maryland and holds a Ph.D. in Biochemistry from the University of Toronto, and a B.Sc. in Applied Biochemistry from the University of Salford, Manchester. << CLOSE

Angus Russell
Angus C. Russell
Chairman of the Board
Learn More >>
Dan Browne
Dan Browne
Co-Founder, President & CEO of Revance Therapeutics, Inc.
Learn More >>
Robert Byrnes
Robert Byrnes
Chair – Compensation Committee
Learn More >>
Mark Foley
Mark Foley
Chair – Audit Committee
Learn More >>
Phyllis Gardner
Phyllis Gardner, M.D.
Learn More >>
Julian S. Gangolli
Julian S. Gangolli
Learn More >>
Philip Vickers
Philip J. Vickers
Chair – Science & Technology
Learn More >>

Fast Facts

TransMTS®

Fact: Revance’s patented TransMTS® excipient is a unique peptide companion technology that may be used for injectable as well as topical drug products of various macromolecules and drug compounds, such as daxibotulinumtoxinA, our highly purified botulinum toxin type A.

DaxibotulinumtoxinA for Injection (RT002)

Fact: RT002 INJECTABLE: Revance’s RT002 investigational product candidate is an injectable, long-acting form of daxibotulinumtoxinA. Based on clinical studies (BELMONT), RT002 holds the potential of longer duration of effect at the target muscle.

Fact: Revance is moving forward with an Investigational New Drug (IND) submission for the Phase 3 clinical program for RT002 in glabellar lines and other supportive studies required for Biologics License Application (BLA) filing. We expect to initiate Phase 3 clinical trials before the end of 2016.

DaxibotulinumtoxinA Topical Gel (RT001)

Fact: Revance’s RT001 early development product candidate is a topical gel formulation of daxibotulinumtoxinA, administered by physicians in a proprietary single-use apparatus.

Fact: RT001 topical gel is designed to eliminate the use of needles, making this a non-invasive procedure that would help avoid pain and bruising associated with injections.

Revance

Fact: Revance manufactures daxibotulinumtoxinA, a highly purified botulinum toxin type A molecule that uses no animal-derived components or human albumin in its production.

Fact: Revance employs in-house, state-of-the-art manufacturing and analytics capabilities, and holds 174 issued patents in the US, EU, Latin America and Asia, as of September, 2016.

Fact: Revance is well-funded to aggressively support its Phase 3 development programs and plans to commercialize RT002 injectable within a few short years.

Market Potential

Fact: Although consumers primarily equate botulinum toxin with anti-aging and wrinkle reduction, the therapeutic uses of botulinum toxin represent the larger slice of the estimated $3.4 billion* global neurotoxin market.

Partnership Opportunities

At Revance, we consistently evaluate opportunities to address unmet or underserved medical needs independently and in association with strategic partners. We welcome these discussions.

If you are interested in pursuing a corporate partnership opportunity with us or would like to discuss Revance’s TransMTS® peptide technology and areas of development interest, please contact us by filling out the form below:

Let us know if you’re interested in partnering with us.

Careers

Working With Us

At Revance, careers and passion come together. We have assembled a team of highly motivated, talented industry professionals who challenge the status quo. Collectively, we aim to improve the patient’s treatment experience by changing the way drugs are delivered. This is no small task, but we believe it is possible. Our team works together each day to achieve that common goal.

We are seeking exceptionally experienced individuals who will immediately contribute to the rapid development of our ambitious product pipeline. Passion, creativity, and a dedication to developing products that improve lives and personal well-being are all a part of our culture.

As an entrepreneurial company, Revance combines a dynamic start-up culture with the structure and stability of a larger corporation. This allows employees to work on exciting projects and technology within an infrastructure that provides guidance and security.

Our Company Values

  • Leadership drives achievement beyond the status quo and inspires others.
  • Scientific data and critical thinking drive our agile decision making.
  • Innovation creates sustained value and is fueled by our entrepreneurial spirit.
  • Collaboration leverages the knowledge & efforts of our diverse teams to achieve results.
  • Quality ensures sustained excellence.
  • Integrity and ethical business conduct guides us in all situations.
  • Accountability is taking ownership and responsibility in everything we do.
Learn More >>

Revance Credo

Commitment to Customers: Our first priority is to the patients, doctors, nurses, and medical practitioners who use our products. We are focused on improving patient quality of life by developing, manufacturing, and marketing innovative therapeutic and aesthetic solutions.

Commitment to Employees: People are our most valuable asset. The company respects the passion, merit, and diversity that each individual brings to the organization. Employees have a duty to the team to operate at the highest standards of excellence, collaboration, and ethics.

Commitment to Shareholders: By capturing and expanding existing markets and creating new ones globally with our botulinum toxin therapies and other pharmaceuticals, we strive to provide superior returns to our investors.

Learn More >>

Company Benefits

Revance recognizes that our employees are the key to our success. We provide a comprehensive set of employee benefit programs that provide financial rewards and supports individual needs. Our benefits represent a value to our employees, above and beyond salary.

We provide the following:

  • Medical, Dental and Vision Insurance
  • Life Insurance
  • Short-Term and Long-Term Disability
  • Flexible Spending Accounts (Healthcare, Dependent Care)
  • Tuition Reimbursement Program
  • 401K Retirement Plan
  • Incentive Stock Plan
  • Employee Stock Purchase Plan
  • Annual Bonus Program
  • Vacation, Sick and Holiday Pay
  • Pre-Tax Commute Program
  • Free Bart Shuttle
  • Free Fitness Center On-site
  • Free Weekly Lunch

Career Opportunities

View our Open Jobs

Contact Us

Revance
7555 Gateway Boulevard
Newark, California 94560
Phone: (510) 742-3400
Fax: (510) 742-3401

RT002 injectable and RT001 topical are investigational product candidates. RT002 is currently undergoing clinical studies for both therapeutic and aesthetic indications. RT001 is in preclinical development.